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LETTERS TO THE EDITOR
Reverse epidemiology and
hemodialysis blood pressure
To the Editor: Analyzing reverse causality in dialysis,
Kalantar-Zadeh et al [1] address the blood pressure (BP)
control issue and refer to Tassin unit experience in this
issue of Kidney International.
In the studies cited by the authors, BP figures used
as risk predictor are baseline values, most patients are
hypertensive, antihypertensives are used in 65%, follow-
up time is <5 years, and extracellular volume (ECV) is
not mentioned. Conversely, in our own studies [2, 3],
integrated BP values are used, BP is strictly normal,
antihypertensives are seldom used, follow-up time is
>10 years, and ECV control is a key point. Among 1235
Tassin patients, the lowest initial predialysis BP decile
(1st dialysis month mean arterial pressure <90 mm Hg)
mortality is significantly high (2 years odds ratio = 1.96,
P < 0.02). Therefore, in Tassin as elsewhere, initially low
BP does predict early mortality.
BP predictive value at dialysis initiation is poor: 90%
of patients then are hypertensive, whatever their former
hypertension exposure duration, and whether or not they
become normotensive in dialysis. The effect of hyperten-
sion on target organs takes many years and very often
we don’t know how long a patient starting dialysis has
been hypertensive. A recent report [4] clearly confirms
the crucial predictive importance of hypertension dura-
tion before dialysis.
Reverse epidemiology has misleading relevance on
dialysis management. The high early mortality univer-
sally associated with low baseline BP figures does not
contradict the need to achieve normal BP in dialysis
patients to reduce long-term cardiovascular mortality.
Besides, the eventual noxious/beneficial role of antihy-
pertensive medications in dialysis patients needs to be
investigated.
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Reply from the Authors
Charra et al [1] indicate that in Tassin, a low, rather
than elevated, blood pressure (BP) is associated with an
almost 2-fold increase in mortality among maintenance
hemodialysis (MHD) patients, despite long hours of dial-
ysis treatment. This is consistent with our stated theory of
reverse epidemiology. The study quoted by the authors in-
dicating a positive association between hypertension and
mortality in 184 Spanish MHD patients had a relatively
small sample size [2]. Moreover, patients in this study
were, on average, 10 years younger than MHD patients
in the United States [3]. On the contrary, the epidemio-
logic studies indicating a strong association between low
BP and mortality in MHD patients, which we [1] referred
to, or which have been published elsewhere [4], examined
many thousands of MHD patients with a low likelihood
of selection bias.
It is not well established that treatment of hyperten-
sion by altering hemodialysis techniques or lengthening
dialysis hours improves survival by reducing BP. Such
treatments almost certainly change many other physio-
logic and metabolic conditions concurrently. Nonethe-
less, it is quite possible that if MHD patients lived longer,
traditional risk factors such as hypertension might have
the time necessary to exert their long-term deleterious
effects. However, in MHD patients, malnutrition-
inflammation complex syndrome (MICS) may indepen-
dently cause high early mortality and reverse traditional
risk factors [1]. Thus, it is possible, although not proven,
that alleviation of MICS saves lives. Given the high mor-
tality in MHD patients and failure of traditional risk
factors to explain this, randomized clinical trials that
test whether treatment of MICS reduces mortality are
strongly indicated.
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